Dirk Menschig leaves Abbott to join SCIderm
This article was originally published in Scrip
Dirk Menschig, previously business unit manager at Abbott, has joined a CRO, SCIderm, as managing director and partner. Mr Menschig spent over seven years at Abbott and was responsible for marketing and sales of its blockbuster drug, Humira (adalimumab).
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.